BURLINGTON, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to ...

SQ Innovation today announced that results of the SUBCUT HF II trial of its product Lasix® ONYU, will be presented at Heart Failure 2026, the annual congress of the Heart Failure Association (HFA) of ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved an expanded indication of self-administered subcutaneous furosemide for patients with HF. The ...

Please provide your email address to receive an email when new articles are posted on . scPharmaceuticals Inc. announced the FDA approved its self-administered subcutaneous furosemide injection for ...

A Prescription Drug User Fee Act target date of July 26, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application ...

For patients with chronic heart failure (HF) who have persistent congestion despite high doses of oral loop diuretics, the right way to intensify diuretics in the outpatient setting may be narrowed, ...

The US Food and Drug Administration (FDA) has approved a furosemide preparation (Furoscix, scPharmaceuticals) intended for subcutaneous self-administration by outpatients with chronic heart failure ...

Loop diuretics, and in particular furosemide, are the most effective agents for the management of signs and symptoms of fluid overload in patients with heart failure (HF). Indeed, through their ...

Associate Professor, Department of Family Medicine, Case Western Reserve University School of Medicine, University Hospitals, Case Medical Center, Cleveland, Ohio Diuretics are considered first-line ...

Furosemide oral tablet is a generic drug FDA-approved to treat high blood pressure in adults and edema (swelling caused by fluid buildup) in adults and some children. As a diuretic (water pill), ...